<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861194</url>
  </required_header>
  <id_info>
    <org_study_id>NL73192.041.20</org_study_id>
    <nct_id>NCT04861194</nct_id>
  </id_info>
  <brief_title>EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT)</brief_title>
  <acronym>ERECT</acronym>
  <official_title>EREctile Function Preservation for Prostate Cancer Radiation Therapy (ERECT); a Prospective Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-arm phase II trial of 70 men with low- or intermediate-risk prostate cancer receiving&#xD;
      magnetic resonance guided adaptive radiotherapy (MRgRT) in 5 fractions of 7.25 Gy,&#xD;
      additionally sparing the neurovascular bundles, the internal pudendal arteries, the corpora&#xD;
      cavernosa, and the penile bulb for erectile function preservation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rationale: Erectile dysfunction is a frequent side effect of external beam radiotherapy&#xD;
      (EBRT) for prostate cancer. To date, anatomy-based treatments that are designed to spare&#xD;
      relevant neurovascular structures such as the internal pudendal artery and neurovascular&#xD;
      bundles have not yet been routinely implemented in clinical practice. The implementation of&#xD;
      magnetic resonance imaging (MRI) in treatment planning and introduction of Intensity&#xD;
      Modulated Radiotherapy (IMRT) and Volumetric Arc Therapy (VMAT) have improved treatment&#xD;
      precision and enabled anatomy-based EBRT and neurovascular-sparing treatments. Spratt et al.&#xD;
      have conducted a single-arm phase 2 study to investigate the effect of vascular-sparing IMRT&#xD;
      treatments, and found a significantly improved 2-year erectile function (78%, 95% confidence&#xD;
      interval [CI] 71-85%) compared to conventional radiotherapy (42%, 95% CI 38-45%; p&lt;0.001) or&#xD;
      nerve-sparing prostatectomy (24%, 95% CI 22-27%; p&lt;0.001). In the UMCU, the state-of-the-art&#xD;
      MRI linear accelerator (MR-Linac) has recently been introduced. This new system allows&#xD;
      radiation delivery under high-precision MRI visualization. The MR-Linac is therefore the most&#xD;
      suitable technique for neurovascularsparing external beam radiotherapy treatments. Such&#xD;
      neurovascular-sparing treatments may substantially improve post-radiotherapy erectile&#xD;
      function outcomes and can thus improve quality of life without substantially compromising&#xD;
      oncologic outcome.&#xD;
&#xD;
      Objective: To investigate preservation of erectile function after MR-guided radiotherapy with&#xD;
      neurovascular-sparing in patients with localized prostate cancer.&#xD;
&#xD;
      Study design: The EREctile function preservation for prostate Cancer radiation Therapy&#xD;
      (ERECT) trial is a prospective, single-center, phase 2 trial. Patients will be treated with&#xD;
      the MR-Linac up to 5 fractions of 7.25 Gy with neurovascular-sparing. All fractions will be&#xD;
      delivered over the course of 2 and a half weeks.&#xD;
&#xD;
      Study population: Men with low- and intermediate-risk adenocarcinoma of the prostate,&#xD;
      clinical stage T1c-T2c, and Gleason ≤7, and iPSA &lt;20 µg/L (NCCN risk categories). Patients&#xD;
      with pT1a/b tumor diagnosis after transurethral resection of the prostate (TURP) are&#xD;
      included, patients with &quot;bulky&quot; iT3 tumor diagnosis are excluded. Baseline erectile function&#xD;
      score according to the International Index of Erectile Function (IIEF-5) questionnaire of at&#xD;
      least 17.&#xD;
&#xD;
      Intervention: All patients will receive MR-Linac treatment consisting of 5 fractions of 7.25&#xD;
      Gy with neurovascular sparing, Fractions will be delivered with an overall treatment time of&#xD;
      two and a half weeks.&#xD;
&#xD;
      Main study parameters/endpoints:&#xD;
&#xD;
      Primary endpoint: the incidence of erectile dysfunction (ED) three years after treatment.&#xD;
&#xD;
      Secondary endpoints: relapse-free survival, acute and late genitourinary and gastrointestinal&#xD;
      toxicity and patient reported quality of life.&#xD;
&#xD;
      Nature and extent of the burden and risks associated with participation, benefit and group&#xD;
      relatedness: Participants will receive neurovascular sparing MR guided radiation therapy&#xD;
      (MRgRT) consisting of 5 fractions of 7.25 Gy. The number of fractions and duration of&#xD;
      treatment is similar to conventional MRgRT consisting of 5 fractions of 7.25 Gy. No increase&#xD;
      in toxicity is expected as the dose constraints for the organs at risk in the neurovascular&#xD;
      sparing plan will be identical to the conventional plan (i.e. bladder, rectum, femoral head&#xD;
      and anal sphincter). For neurovascular sparing treatment, the protocol is extended with dose&#xD;
      constraints for newly identified organs at risk (i.e. neurovascular bundles (NVB), internal&#xD;
      pudendal arteries (IPA), corpora cavernosa (CC) and penile bulb (PB)). Attention for these&#xD;
      organs at risk during treatment planning may reduce erectile dysfunction for the&#xD;
      neurovascular sparing treatment. The dose to the dorsolateral part of the prostate might be&#xD;
      lower in the NVB sparing plan as the NVB lies in close proximity to this part of the&#xD;
      prostate. A slight dose concession on the dorsolateral part of the prostate will only be&#xD;
      permitted if the visible tumor on multiparametric MRI is not in vicinity of the NVB as&#xD;
      underdosage of the dominant index lesion is undesirable for tumor control. A lower dose to&#xD;
      the dorsolateral part of the prostate may have an impact on biochemical control for certain&#xD;
      cases, but we do not expect that it will influence overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 14, 2021</start_date>
  <completion_date type="Anticipated">August 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">August 10, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Erectile dysfuntion</measure>
    <time_frame>3 years</time_frame>
    <description>Erectile function score of ≤11 on the International Index of Erectile Function (IIEF) -5 questionnaire (0=worst; 25=best)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as biochemical relapse, or positive PSMA scan or clinical relapse whichever occurs first. Biochemical relapse is defined according to the Phoenix definition, i.e. a PSA greater than the current Nadir plus 2 ng/mL. Clinical relapse consists either of locoregional disease or distant metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>According to the Expanded Prostate Cancer Index Composite short form (EPIC-26) questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute and late gastrointestinal and genitourinary toxicity</measure>
    <time_frame>3 years</time_frame>
    <description>According to the Common Terminology Criteria for Adverse Events version 5</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Erectile Dysfunction Following Radiation Therapy</condition>
  <arm_group>
    <arm_group_label>Neurovascular-sparing 5x7.25 Gy MRgRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MRgRT to the prostate in 5 fractions of 7.25 Gy, additionally sparing the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Neurovascular-sparing</intervention_name>
    <description>Dose reduction of the neurovascular bundles, internal pudendal arteries, corpora cavernosa, and penile bulb during 5x7.25 Gy MRgRT</description>
    <arm_group_label>Neurovascular-sparing 5x7.25 Gy MRgRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Histologically proven adenocarcinoma of the prostate&#xD;
&#xD;
          -  Low-risk or intermediate-risk prostate cancer according to NCCN risk categories (low&#xD;
             risk: T1c-T2a, Gleason score ≤6, and PSA &lt;10 µg/L; intermediate risk: T2b-T2c or&#xD;
             Gleason score 7 or PSA 10-20 µg/L)&#xD;
&#xD;
          -  Patients with pT1a/b tumor diagnosis after transurethral resection of the prostate&#xD;
             (TURP)&#xD;
&#xD;
          -  Domain score of 17-25 on the International Index of Erectile Function-5 (IIEF-5)&#xD;
             questionnaire&#xD;
&#xD;
          -  Karnofsky score of 70-100&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of (neo-)adjuvant androgen deprivation therapy&#xD;
&#xD;
          -  High-risk prostate cancer according to NCCN risk categories (T3a or Gleason score 8-10&#xD;
             or PSA &gt;20 µg/L)&#xD;
&#xD;
          -  Patients with &quot;bulky&quot; iT3 tumor diagnosis&#xD;
&#xD;
          -  Previous pelvic irradiation or radical prostatectomy&#xD;
&#xD;
          -  Clinical evidence of metastatic disease&#xD;
&#xD;
          -  Patients who are unable to undergo MRI&#xD;
&#xD;
          -  Patients who are incompetent to sign written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jochem RN van der Voort van Zyp, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederik R Teunissen, MD</last_name>
    <phone>+31 (0)887550474</phone>
    <email>f.r.teunissen@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jochem RN van der Voort van Zyp, MD PhD</last_name>
    <email>j.r.n.vandervoortvanzyp@umcutrecht.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frederik R Teunissen, MD</last_name>
      <email>f.r.teunissen@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Ruud C Wortel, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frederik R Teunissen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jochem RN van der Voort van Zyp, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>Helena M Verkooijen</investigator_full_name>
    <investigator_title>Prof.dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

